Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
| Status: | Archived |
|---|---|
| Conditions: | Psoriasis, Infectious Disease, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2010 |
| End Date: | February 2011 |
Use of Altabax Ointment (Retapamulin 1%) BID for 5 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study
Skin infections may complicate the treatment of atopic dermatitis.The use of topical
ointments has become very important to avoid the use of oral antibiotics. There is little
supporting literature regarding the use of topical antibiotics in secondarily infected
atopic dermatitis.
This study will investigate the safety and effectiveness of Altabax ointment use in treating
secondarily infected atopic dermatitis caused by Staphylococcus aureus and Streptococcus
pyogenes.
Atopic dermatitis patients are commonly secondarily infected with Staphylococcus aureus
and/or Streptococcus pyogenes, more recently with Methicillin-resistant Staphylococcus
aureus (MRSA), due to impaired barrier function. As cutaneous infections such as MRSA and
others may complicate the treatment of atopic dermatitis, the use of topical antibiotics
have become very important to avoid oral antibiotics and their side effects, especially in
the pediatric population.
The current study will investigate the safety and efficacy of Altabax ointment use for
treatment of secondarily infected lesions caused by Staphylococcus aureus and Streptococcus
pyogenes in both the pediatric and adult populations.
We found this trial at
1
site
Click here to add this to my saved trials
